CYTK
CYTOKINETICS INC
$68.45
+0.81%
$8.4B
No data for this timeframe.
Vol
Market Cap$8.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders9 funds
Inst. Value$2.0B
Inst. Activity3 buys / 1 sells
Insider Activity0B / 14S
Insider Net $-$10.2M
SEC Reports12
Press Releases6
Recent Activity
Nov 14, 2026
fda_pdufa
PDUFA: CYTK — aficamten in obstructive hypertrophic cardiomyopathy — 2026-11-14
FDA target action date 2026-11-14 for CYTK (CYTOKINETICS INC). Drug: aficamten. Indication: obstruct
Jun 9, 2026
Insider
Malik Fady Ibraham sold 3,500 shares
EVP Research & Development @ $7.80 ($27.3K)
Jun 9, 2026
Insider
Malik Fady Ibraham sold 3,500 shares
EVP Research & Development @ $67.98 ($237.9K)
Jun 9, 2026
Insider
Malik Fady Ibraham sold 3,500 shares
EVP Research & Development @ $0.00 ($0.00)
Jun 1, 2026
SEC
Two insiders at Cytokinetics, including the President & CEO, sold a total of $949K in open-market sales over a one-week
CLUSTER — Impact 3/10
May 20, 2026
SEC
CEO Robert Blum and EVP Fady Malik sold a total of $849K in open-market transactions within a week of a $700M equity off
CLUSTER — Impact 3/10
May 5, 2026
SEC
Cytokinetics filed a preliminary prospectus supplement for a $650M common stock offering, underwritten by Morgan Stanley
424B5 — Impact 6/10
Inst.
NORGES BANK — NEW
807,070 shares ($51.3M)
Price Targets
$104.70
+53.0% upside
Strong Buy
Current $68.45
Low $69.00
Median $104.00
High $146.00
20 analysts
$69.00
$146.00
Analyst Ratings
6Strong Buy
18Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | Citigroup | INITIATE | Buy |
| May 12, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 7, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 6, 2026 | Stifel | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.64 ▲ +2.2% | $-2.02 — $-1.26 | -47% YoY | 15 |
| Next Q | $-1.59 ▲ +3.6% | $-1.90 — $-1.05 | -3% YoY | 15 |
| Current FY | $-6.43 ▲ +2.2% | $-7.47 — $-4.80 | 2% YoY | 15 |
| Next FY | $-4.75 ▲ +4.4% | $-5.61 — $-3.39 | 26% YoY | 14 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Two insiders at Cytokinetics, including the President & CEO, sold a total of $949K in open-market sales over a one-week
Jun 1, 2026
NEUTRAL
CLUSTER
3/10
CEO Robert Blum and EVP Fady Malik sold a total of $849K in open-market transactions within a week of a $700M equity off
May 20, 2026
NEUTRAL
Press
4/10
Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing the clinical profile of MYQORZO (aficamten) in obs
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $813.8M | — |
| VANGUARD GROUP INC | $765.5M | — |
| BANK OF AMERICA CORP | $186.9M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $87.9M | NEW |
| MORGAN STANLEY | $80.4M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Malik Fady | M | $27.3K |
| Jun 9, 2026 | Malik Fady | SELL | $237.9K |
| Jun 9, 2026 | Malik Fady | M | $0.00 |
| Jun 1, 2026 | PARSHALL B | SELL | $370.4K |
| Jun 1, 2026 | Callos Andrew | M | $348.9K |
9 institutional holders with $2.0B total value (31,860,483 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, BANK. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 12,807,752 | $813.8M | 40.2% | — |
| 2 | VANGUARD GROUP INC | 12,048,131 | $765.5M | 37.8% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 2,941,152 | $186.9M | 9.2% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,383,437 | $87.9M | 4.3% | NEW |
| 5 | MORGAN STANLEY | 1,265,301 | $80.4M | 4.0% | ADD +36.1% |
| 6 | NORGES BANK | 807,070 | $51.3M | 2.5% | NEW |
| 7 | TWO SIGMA INVESTMENTS, LP | 274,017 | $17.4M | 0.9% | NEW |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 172,067 | $10.9M | 0.5% | TRIM -40.7% |
| 9 | WELLS FARGO & COMPANY/MN | 161,556 | $10.3M | 0.5% | ADD +65.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 807,070 | — | $51.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 274,017 | — | $17.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 289,967 | 172,067 | -40.7% | $10.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 97,560 | 161,556 | +65.6% | $10.3M | 2025-Q4 |
| UBS Group AG | TRIM | 3,070,665 | 1,823,051 | -40.6% | $100.2M | 2025-Q3 |
| MORGAN STANLEY | ADD | 1,118,080 | 1,521,186 | +36.1% | $83.6M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,167 | 289,967 | +2752.0% | $15.9M | 2025-Q3 |
| NORGES BANK | EXIT | 1,184,072 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | ADD | 2,134,219 | 3,070,665 | +43.9% | $101.5M | 2025-Q2 |
| NORGES BANK | NEW | — | 1,184,072 | — | $39.1M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 73,966 | 95,350 | +28.9% | $3.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 120,667 | 10,167 | -91.6% | $335.9K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 44,156 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | ADD | 1,201,999 | 2,134,219 | +77.6% | $85.8M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 192,167 | 120,667 | -37.2% | $4.8M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 91,171 | 44,156 | -51.6% | $1.8M | 2025-Q1 |
| NORGES BANK | EXIT | 989,721 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 1,323,791 | 1,761,945 | +33.1% | $82.9M | 2024-Q4 |
| UBS Group AG | DOUBLED | 314,159 | 1,201,999 | +282.6% | $56.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 57,534 | 73,782 | +28.2% | $3.5M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,321,391 | — | $69.8M | 2024-Q3 |
13 unique insiders with 14 transactions. Net insider value: -$10.2M ($0.00 bought, $10.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Malik Fady Ibraham | EVP Research & Development | M | 3,500 | $7.80 | $27.3K |
| Jun 9, 2026 | Malik Fady Ibraham | EVP Research & Development | SELL | 3,500 | $67.98 | $237.9K |
| Jun 9, 2026 | Malik Fady Ibraham | EVP Research & Development | M | 3,500 | $0.00 | $0.00 |
| Jun 1, 2026 | PARSHALL B LYNNE | Director | SELL | 5,000 | $74.08 | $370.4K |
| Jun 1, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 15,000 | $23.26 | $348.9K |
| Jun 1, 2026 | Callos Andrew | EVP, Chief Commercial Officer | SELL | 15,000 | $74.08 | $1.1M |
| Jun 1, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 15,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Kaye Edward M. MD | Director | SELL | 2,933 | $76.09 | $223.2K |
| May 27, 2026 | Wysenski Nancy | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | Wysenski Nancy | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | WIERENGA WENDELL | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | WIERENGA WENDELL | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | Landry Robert E | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | Landry Robert E | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | PARSHALL B LYNNE | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | PARSHALL B LYNNE | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | Kaye Edward M. MD | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | Kaye Edward M. MD | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | HENDERSON JOHN T | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | HENDERSON JOHN T | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | Harrington Robert Arthur | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | Harrington Robert Arthur | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | Daly James M | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | Daly James M | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | Bhanji Muna | Director | A | 2,851 | $0.00 | $0.00 |
| May 27, 2026 | Bhanji Muna | Director | A | 4,301 | $0.00 | $0.00 |
| May 27, 2026 | Blum Robert I | President & CEO | SELL | 7,500 | $77.21 | $579.1K |
| May 19, 2026 | Malik Fady Ibraham | EVP Research & Development | M | 3,500 | $7.80 | $27.3K |
| May 19, 2026 | Malik Fady Ibraham | EVP Research & Development | SELL | 3,500 | $75.69 | $264.9K |
| May 19, 2026 | Malik Fady Ibraham | EVP Research & Development | M | 3,500 | $0.00 | $0.00 |
| May 14, 2026 | Blum Robert I | President & CEO | SELL | 7,500 | $77.92 | $584.4K |
| May 5, 2026 | Malik Fady Ibraham | EVP Research & Development | M | 3,500 | $7.80 | $27.3K |
| May 5, 2026 | Malik Fady Ibraham | EVP Research & Development | SELL | 3,500 | $77.37 | $270.8K |
| May 5, 2026 | Malik Fady Ibraham | EVP Research & Development | M | 3,500 | $0.00 | $0.00 |
| May 5, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 11,333 | $39.13 | $443.5K |
| May 5, 2026 | Callos Andrew | EVP, Chief Commercial Officer | SELL | 11,333 | $77.25 | $875.5K |
| May 5, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 11,333 | $0.00 | $0.00 |
| May 5, 2026 | Lee Sung | EVP, Chief Financial Officer | SELL | 23,906 | $76.87 | $1.8M |
| May 5, 2026 | HENDERSON JOHN T | Director | M | 20,000 | $7.61 | $152.2K |
| May 5, 2026 | HENDERSON JOHN T | Director | SELL | 20,000 | $75.97 | $1.5M |
| May 5, 2026 | HENDERSON JOHN T | Director | M | 20,000 | $0.00 | $0.00 |
| May 5, 2026 | WIERENGA WENDELL | Director | M | 4,032 | $12.40 | $50.0K |
| May 5, 2026 | WIERENGA WENDELL | Director | SELL | 4,032 | $75.00 | $302.4K |
| May 5, 2026 | WIERENGA WENDELL | Director | M | 4,032 | $0.00 | $0.00 |
| May 1, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 15,857 | $37.63 | $596.7K |
| May 1, 2026 | Callos Andrew | EVP, Chief Commercial Officer | SELL | 15,857 | $65.00 | $1.0M |
| May 1, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 15,857 | $0.00 | $0.00 |
| Apr 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 15,000 | $23.26 | $348.9K |
| Apr 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | SELL | 15,000 | $63.26 | $948.9K |
| Apr 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M | 15,000 | $0.00 | $0.00 |
12 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 3 mixed, 6 neutral. Avg impact: 4.5/10.
NEUTRAL
CLUSTER
3/10
Two insiders at Cytokinetics, including the President & CEO, sold a total of $949K in open-market sa
Jun 1, 2026
NEUTRAL
CLUSTER
3/10
CEO Robert Blum and EVP Fady Malik sold a total of $849K in open-market transactions within a week o
May 20, 2026
MIXED
424B5
6/10
Cytokinetics filed a preliminary prospectus supplement for a $650M common stock offering, underwritt
May 5, 2026
MIXED
CLUSTER
4/10
Multiple CYTK insiders, including CFO and CCO, sold shares totaling $4.53M on the same day as Q1 202
May 5, 2026
NEUTRAL
CLUSTER
3/10
Two insiders at Cytokinetics sold a combined $2.39M in open-market stock on May 5, 2026, the same da
May 5, 2026
NEUTRAL
8-K
3/10
Cytokinetics released a corporate presentation updating on commercial launch progress of MYQORZO (af
May 5, 2026
NEUTRAL
PRESS-RELEASE
3/10
Cytokinetics announced a scheduled date for its Q1 2026 earnings release on May 5, 2026, with a subs
Apr 21, 2026
BEARISH
CLUSTER
7/10
Two top executives at Cytokinetics, including the CEO and Chief Commercial Officer, sold nearly $1 m
Apr 15, 2026
BEARISH
CLUSTER
6/10
Three corporate insiders at Cytokinetics sold shares in the past week, totaling $964K in open-market
Apr 8, 2026
NEUTRAL
144
3/10
Fady Malik, an officer at Cytokinetics, filed a Form 144 to notify intent to sell 22,000 shares of c
Apr 7, 2026
BEARISH
CLUSTER
6/10
Two top executives at Cytokinetics, including CEO Robert Blum, sold shares in a coordinated 7-day wi
Apr 1, 2026
MIXED
8-K
7/10
Cytokinetics reported its transition to a commercial-stage company following FDA, China, and EU appr
Feb 24, 2026
NEUTRAL
4/10
Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing the clinical profile of MYQORZ
May 11, 2026
BEARISH
6/10
Cytokinetics closed an underwritten public offering of 11.3 million shares at $71.00 per share, rais
May 8, 2026
BEARISH
6/10
Cytokinetics priced a $700 million public offering of 9.86 million shares at $71.00 per share, with
May 7, 2026
BULLISH
8/10
Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial of aficamten in no
May 5, 2026
NEUTRAL
3/10
Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-ob
May 4, 2026
NEUTRAL
3/10
Cytokinetics announced nine presentations at the ESC Heart Failure 2026 Congress, including a late-b
Apr 28, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 28 analysts: 6 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$104.70 mean target
+53.0% upside
Strong Buy (1.59)
$69.00 Low
$146.00 High
| Metric | Value |
|---|---|
| Current Price | $68.45 |
| Target Low | $69.00 |
| Target Mean | $104.70 |
| Target Median | $104.00 |
| Target High | $146.00 |
| # Analysts | 20 |
| Recommendation | Strong Buy (1.59) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.64 | $-2.02 | $-1.26 | -46.5% | +2.2% | 9↑ 3↓ | $0.0B | -74.2% | 15 |
| Next Q 2026-09-30 |
$-1.59 | $-1.90 | $-1.05 | -3.1% | +3.6% | 9↑ 4↓ | $0.0B | 1291.9% | 15 |
| Current FY 2026-12-31 |
$-6.43 | $-7.47 | $-4.80 | 1.6% | +2.2% | 8↑ 5↓ | $0.1B | 24.1% | 15 |
| Next FY 2027-12-31 |
$-4.75 | $-5.61 | $-3.39 | 26.1% | +4.4% | 8↑ 4↓ | $0.4B | 254.5% | 14 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.641 | |
| 7d ago | $-1.668 | +0.027 |
| 30d ago | $-1.677 | +0.036 |
| 60d ago | $-1.663 | +0.023 |
| 90d ago | $-1.530 | -0.111 |
16 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | Citigroup | INITIATE | — | Buy |
| May 12, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 7, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | Stifel | MAINTAIN | Buy | Buy |
| May 6, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Wells Fargo | INITIATE | — | Overweight |
| Apr 6, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 18, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 6, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Feb 26, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 25, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 3, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| Jan 20, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Dec 23, 2025 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Dec 22, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Dec 22, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 22, 2025 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Dec 22, 2025 | Needham | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Goldman Sachs | UPGRADE | Neutral | Buy |
| Dec 12, 2025 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 18 | 4 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 18 | 4 | 0 | 0 | 85% | |
| Apr 1, 2026 | 5 | 17 | 4 | 0 | 0 | 85% | |
| Mar 1, 2026 | 5 | 17 | 4 | 0 | 0 | 85% | |
| Feb 1, 2026 | 5 | 17 | 4 | 0 | 0 | 85% | |
| Jan 1, 2026 | 5 | 17 | 4 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Nov 14, 2026
fda_pdufa
PDUFA: CYTK — aficamten in obstructive hypertrophic cardiomyopathy — 2026-11-14
FDA target action date 2026-11-14 for CYTK (CYTOKINETICS INC). Drug: aficamten. Indication: obstructive hypertrophic cardiomyopathy. sNDA for aficamte
Jun 10, 2026
Clinical Trial
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Phase Phase 3 — COMPLETED
Jun 8, 2026
other
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
<p align="center"><em>Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values</em></p>
Jun 3, 2026
short_volume
Short Volume: CYTK — 57.3% short (0.3M / 0.5M)
Short: 307,493 | Exempt: 25 | TRF Vol: 536,903 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: CYTK — 67.1% short (0.4M / 0.6M)
Short: 383,361 | Exempt: 4,899 | TRF Vol: 571,649 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
<p align="center"><em>European Launch Follows Strong U.S. Start</em></p>
Jun 1, 2026
short_volume
Short Volume: CYTK — 56.7% short (0.4M / 0.7M)
Short: 382,002 | Exempt: 670 | TRF Vol: 673,910 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: CYTK — 55.7% short (0.3M / 0.6M)
Short: 315,771 | Exempt: 152 | TRF Vol: 566,633 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
Cytokinetics to Participate in June Investor Conferences
<p align="justify">SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that memb
May 27, 2026
short_volume
Short Volume: CYTK — 78.0% short (0.6M / 0.8M)
Short: 600,980 | Exempt: 28,782 | TRF Vol: 770,832 | Short Ratio: 78.0% | Off-exchange volume (dark pool + OTC)
May 20, 2026
routine
Cytokinetics to Hold Annual Meeting of Stockholders
<p align="justify">SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its
May 19, 2026
short_volume
Short Volume: CYTK — 56.7% short (0.6M / 1.0M)
Short: 588,687 | Exempt: 3,493 | TRF Vol: 1,038,550 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
other
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on M
May 15, 2026
short_volume
Short Volume: CYTK — 76.6% short (0.5M / 0.6M)
Short: 461,233 | Exempt: 942 | TRF Vol: 601,857 | Short Ratio: 76.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: CYTK — 27,719 shares ($2.1M) failed to deliver
Settlement: 20260513, Price: $74.81, FTD Value: $2,073,658.39, CYTOKINETICS INC COM STK NEW (
May 12, 2026
other
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
<p align="justify">SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that memb
Mar 30, 2026
Clinical Trial
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Phase Phase 3 — ACTIVE_NOT_RECRUITING